Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Down – What’s Next?

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) gapped down prior to trading on Monday . The stock had previously closed at $10.54, but opened at $9.38. Lexeo Therapeutics shares last traded at $7.6610, with a volume of 706,605 shares trading hands.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Cantor Fitzgerald began coverage on Lexeo Therapeutics in a research report on Monday, December 1st. They issued an “overweight” rating and a $19.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday. Leerink Partners upped their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. HC Wainwright cut their price objective on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Guggenheim initiated coverage on Lexeo Therapeutics in a report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Lexeo Therapeutics Price Performance

The firm has a fifty day simple moving average of $9.45 and a 200 day simple moving average of $7.13. The company has a market capitalization of $563.48 million, a price-to-earnings ratio of -2.86 and a beta of 1.75.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.15. Research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Insider Buying and Selling at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 13,133 shares of the company’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $117,409.02. Following the transaction, the chief executive officer directly owned 242,118 shares of the company’s stock, valued at approximately $2,164,534.92. The trade was a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Adler sold 3,382 shares of the company’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $30,235.08. Following the sale, the insider directly owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. This represents a 4.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 24,646 shares of company stock valued at $221,037 in the last three months. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXEO. CWM LLC grew its stake in shares of Lexeo Therapeutics by 150.3% during the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after acquiring an additional 6,216 shares in the last quarter. Ethic Inc. bought a new stake in Lexeo Therapeutics in the second quarter worth approximately $44,000. Cerity Partners LLC acquired a new stake in Lexeo Therapeutics in the 2nd quarter valued at $50,000. Intech Investment Management LLC lifted its position in shares of Lexeo Therapeutics by 20.7% during the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after purchasing an additional 2,342 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Lexeo Therapeutics during the 2nd quarter worth approximately $60,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.